David B. Solit, MD

Chief, Molecular Medicine Service; Geoffrey Beene Chair; Co-Director, Kravis Center for Molecular Oncology, Memorial Sloan Kettering Cancer Center

[David B. Solit, MD @DSolit]

It has been a year since my last update on the prospective MSK-IMPACT/ACCESS sequencing cohort, now >120,000 tumor/cfDNA samples analyzed. Thanks to the patients, docs, nurses, techs, data scientists who have contributed. So where are we going next:

[Dan Landau @landau_lab]

Faculty ad is out,

please help spread the word

Come #DreamBig together, without a doubt,

in the best city in the world!

https://t.co/dhSlHbbfJ0

[David H Aggen, MD PhD @Dr_Aggen]

As discussed at #ESMO26, data on EV+P in bladder cancer with variant histology remain limited.

Together with Emory and Dr. Jacqueline Brown, we’re studying EV+P in tumors with aberrant histologic features including with squamous, plasmacytoid, and glandular features.

MSK PI: Dr. Sam Funt.

@OncoAlert

More info here: https://t.co/vTO2h1aF9u

https://t.co/EdeZIrTonS

#bladdercancer #esmo2026

[Jonathan Rosenberg MD @DrRosenbergMSK]

The MSKCC Genitourinary Oncology Service is looking for a motivated, patient-centered, clinical investigator with a focus on urothelial cancer. Join a great team focused on eradicating GU cancers!

https://t.co/vRUXraSPOB

[Himanshu Nagar @HimanshuNagarMD]

Join MSK faculty Oct. 8–9, 2026 for a hybrid 2-day course on the latest advances in multidisciplinary prostate cancer care—from risk assessment and imaging to local and systemic therapies. Attend onsite in NYC or virtually via Zoom. #ProstateCancer
Register here: https://t.co/8f70nRT2TY

[Himanshu Nagar @HimanshuNagarMD]

🚨 We’re hiring at MSK!

🎯 Director, Metastatic Disease Team
👥 Lead ~20 faculty
🧪 Drive innovative trials
🔬 ~50% research time (track-dependent)
🌐 Shape care across @MSKCancerCenter
Help define what’s next in @MSK_RadOnc. 🚀

Contact @seanmmcbride if interested.

Click here for more details: https://t.co/jwm0KSmt8b

[James J. Harding, MD @HardingJJMD]

Congratulations @CowzerDarren. Great deep dive #biliarytractcancer #genomics outcomes and resistance! @MSK_DeptOfMed @MSKCancerCenter @MskccCMO @DSolit @GABOUALFA @EileenMOReilly

[ari hakimi @arihakimi]

Why do VEGFR-TKI + IO combinations produce impressive responses in ccRCC but often fail to achieve the long-term durability seen with dual checkpoint blockade? Check out our lab's latest in @Cancer_Cell led by the incredible Lyn Vuong!
https://t.co/ASvkCpDzQW

[Memorial Sloan Kettering Cancer Center @MSKCancerCenter]

Congratulations to Dr. Martin Weiser, who has been selected to serve serve as the next Chair of the Department of Surgery at MSK.

Dr. Weiser currently holds the Stuart H.Q. Quan Chair in Colorectal Surgery, is a world-renowned academic colorectal surgeon, and has held a number of important leadership roles in his 25 years on the faculty at MSK, including serving for the past 10 months as the Acting Department Chair.

Join us in welcoming Dr. Weiser to the role of Chair of the Department of Surgery by commenting below. 👏

[Ziad Bakouny, MD, MSc @ZiadBakouny]

Really awesome poster by urologic oncology fellow extraordinaire @VinceDAndreaMD with @DrDarrenFeldman @DSolit #SamFunt on genomic determinants of cisplatin resistance in germ cell tumors!
@MSKCancerCenter @UrologyMSK @MSK_DeptOfMed

@ConquerCancerFd @ASCO #ASCO26

[Jiaqian(Josie) Luo @luo_jiaqian]

A truly memorable #AACR26! Honored to present our work on bladder cancer lineage plasticity and grateful to receive the Scholar-in-Training Award. Huge thanks to my mentor @DSolit, collaborators, and labmates for their guidance and support #BladderCancer #CancerResearch

[Memorial Sloan Kettering Cancer Center @MSKCancerCenter]

Today, MSK physician-scientist Dr. Sarat Chandarlapaty shared his research on how #cancer develops resistance to #HER2 antibody-drug conjugates during a session at #AACR26.

[MSK Department of Medicine @MSK_DeptOfMed]

On the #AACR26 stage this morning: Dr. Yelena Janjigian, Chief of MSK's Gastrointestinal Oncology Service, will share her expertise on the latest advances in #cancer #immunotherapy. @MSKCancerCenter @AACR @YJanjigianMD

⏰ 10:15 a.m. PDT

https://t.co/gTKUeKZuAJ

[Carissa Chu @CChuMD]

Great to see @DSolit today at #AACR26. Truly incredible mentor along with @jonchou05
So much on plasticity in bladder cancer yet to explore.
Cut to Tamilla and I continuing to look through our data over tapas 🤓 💃🏻

[MSK Department of Medicine @MSK_DeptOfMed]

Happening soon at #AACR26: Dr. David Solit is leading a session sharing how the @AACR international registry Project GENIE® is advancing #cancer research. @MSKCancerCenter @DSolit

⏰ 2:30 p.m. PDT

https://t.co/MQmoLd7Kuz

[Memorial Sloan Kettering Cancer Center @MSKCancerCenter]

Every medical breakthrough begins with a decades-long journey in the laboratory, a key message shared during #AACR26.

Our MSK #SavedbyScience series, captures the emotional meetings between patients and the scientists, including physician-scientist and AACR presenter Dr. @DSolit, whose years of research have given them new hope.

Watch more Saved by Science stories on YouTube: https://t.co/X3ZgrWTiiJ @AACR

[Memorial Sloan Kettering Cancer Center @MSKCancerCenter]

MSK physician-scientist Dr @DSolit presented about advancing target discovery for rare cancers through institutional-scale molecular profiling and social media outreach at #AACR26. @AACR

[Wungki Park, MD MS @CentralParkWMD]

1/n

Setidegrasib the first-in-human, first-in-class, KRAS G12D-targeted protein degrader #TPD

Our KRAS G12D degrader study is now published in the New England Journal of Medicine @NEJM
https://t.co/8Juil6VN42

A new way to target KRAS G12D - one of the most common oncogenic drivers across cancers.

[James J. Harding, MD @HardingJJMD]

Thank you @GABOUALFA, @MSK_DeptOfMed for many years of mentorship/support in #HPB cancers. Amazing to win this @theNCI #R01 award. @EileenMOReilly , @YJanjigianMD @DSolit @OlcaBasturk @MskccCMO @MSKBiostats @MSKCancerCenter

[Ghassan Abou-Alfa @GABOUALFA]

Congratulations @HardingJJMD on your #R01. @MSKCancerCenter @MSK_DeptOfMed and all colleagues are happy for you!

[David B. Solit, MD @DSolit]

@Dr_Aggen making a strong case for routine biomarker testing as a guide to systemic therapy in patients with urothelial cancer.

[David H Aggen, MD PhD @Dr_Aggen]

Enjoying a Saturday at #NYGU #GOTOPER with @DSolit reviewing ADC target expression in variant histology bladder cancer. Fantastic work in collaboration with @h_alahmadie #GU #NYGU26